Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
Latest Information Update: 03 Feb 2026
At a glance
- Drugs Mivocabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 23 Jan 2026 Planned End Date changed from 1 Jun 2027 to 1 Feb 2027.
- 23 Jan 2026 Planned primary completion date changed from 1 Jun 2026 to 1 Feb 2026.
- 24 Sep 2025 Results presented in the Kyverna Therapeutics Media Release.